01/15/2013 | Press release

Myriad Genetics to Announce Second Fiscal Quarter 2013 Results on Tuesday, February 5, 2013

distributed by noodls on 01/15/2013 16:36

Print Print

Sharing and Personal Tools

January 15, 2013

Myriad Genetics to Announce Second Fiscal Quarter 2013 Results on Tuesday, February 5,

2013

SALT LAKE CITY, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the second fiscal quarter 2013 following the close of market on Tuesday, February 5, 2013.
The Company will also host a conference call on Tuesday, February 5, 2013 at 4:30 P.M. Eastern to review the financial results. Participating on the call will be: Peter Meldrum, President and Chief Executive Officer, Mark Capone, President of Myriad Genetic Laboratories, Inc. and Jim Evans, Chief Financial Officer.
To listen to the call, interested parties within the U.S. may dial 800-732-6870, or +1 212-231-2900 for international callers. All callers will be asked to reference reservation number 21645936.
The conference call will also be available through a live webcast at www.myriad.com.
A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-
8284 within the U.S. or +1 402-977-9140 for international callers, and entering reservation number 21645936.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

CONTACT: Scott Gleason

Sr. VP Investor Relations (801) 584-1143 sgleason@myriad.com

Source: Myriad Genetics, Inc. News Provided by Acquire Media

Back

View original format